China Medical System Holdings (CMS) expanded its AI collaboration with Insilico Medicine, targeting CNS disorders with a new agreement framed around a “mass-market” indication. The collaboration builds on Insilico’s generative AI drug discovery platform and CMS’s development and commercialization capabilities. The deal format signals CMS’s strategy to use Insilico’s pipeline acceleration to capture earlier CNS opportunities, particularly where large populations can justify faster scale-up if preclinical and clinical targets translate effectively.